Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988376 | 0.94 | TAAR1 (0.53) | HPGDTAAR1FFAR1ALDH1A1MEN1 | |
| SCHEMBL11615931 | 0.92 | TAAR1 (0.51) | HPGDTAAR1FFAR1ALDH1A1MEN1 | |
| SCHEMBL12132006 | 0.88 | ALDH1A1 (0.49) | HPGDTAAR1FFAR1ALDH1A1MEN1 | |
| SCHEMBL28343241 | 0.86 | ALDH1A1 (0.44) | HPGDTAAR1FFAR1ALDH1A1MEN1 | |
| SCHEMBL2477399 | 0.84 | F13A1 (0.47) | HPGDTAAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL31261412 | 0.84 | F13A1 (0.47) | HPGDTAAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL27641655 | 0.84 | F13A1 (0.47) | HPGDTAAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL4558608 | 0.84 | F13A1 (0.47) | HPGDTAAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL9533116 | 0.84 | F13A1 (0.47) | HPGDTAAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL9812097 | 0.83 | ALDH1A1 (0.43) | HPGDTAAR1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119013024-A | Ligand-drug conjugate of camptothecin analogue, intermediate, preparation method, pharmaceutical composition and application thereof | 上海盟科药业股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118924913-A | Novel camptothecin analogue ligand-drug conjugate, intermediate, pharmaceutical composition and application thereof | 上海盟科药业股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20180028552-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2018-02-01 | — | — | US | disclosed |
| WO-2016123626-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| EP-0262388-B1 | DERIVATIVES OF 2-TERT.-BUTYL-4-METHYL-CYCLOHEXANOL, THEIR PREPARATION AND USE AS FRAGRANCE COMPOUNDS | BASF Aktiengesellschaft (DE) | 1992-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028552-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, EZH2, EHMT1 | HPGD 2762/4885TAAR1 4228/4885FFAR1 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.